<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.108233</article-id><article-id pub-id-type="publisher-id">ACM-36934</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200800000_64036989.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  新型冠状病毒肺炎与心脏损伤相关性的Meta分析
  Meta Analysis of the Correlation between COVID-19 and Heart Injury
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>小玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>再伟</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>虎</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>中兴</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>崔</surname><given-names>志远</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>莎莎</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>侯</surname><given-names>丽娟</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>颖</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>济宁市第一人民医院心血管内科，山东 济宁；济宁市第一人民医院心血管病研究所，山东 济宁</addr-line></aff><aff id="aff4"><addr-line>济宁市第一人民医院心血管内科，山东 济宁</addr-line></aff><aff id="aff2"><addr-line>济宁医学院临床医学院，山东 济宁；济宁市第一人民医院心血管内科，山东 济宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2020</year></pub-date><volume>10</volume><issue>08</issue><fpage>1554</fpage><lpage>1565</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：通过meta分析评价新型冠状病毒肺炎与心脏损伤的相关性，为临床提供循证依据。方法：计算机检索万方、知网、中国生物医学文献数据库、PubMed、Embase、Cochrane Library、Medline数据库，检索感染新型冠状病毒肺炎与心脏损伤的相关研究，检索时间区间均从2020年1月1日至2020年4月20日。对于纳入的研究，应用Rev Man5.3及STATA软件进行分析。结果：总共纳入29项研究，合计4466名患者。Meta分析结果示：危重型患者比非危重型患者有更高的肌钙蛋白(p = 0.03)；合并心肌损伤的患者病情更重、死亡率更高(p = 0.002; p &lt; 0.0001)；此外，患有冠心病、糖尿病或高血压的患者感染新型冠状病毒肺炎后比普通人群感染后病情更重，死亡率更高(p &lt; 0.01)；CK-MB、AST、肌红蛋白、NT-proBNP也对判断病情严重程度有一定价值。结论：合并心脏损伤的新冠肺炎患者病情更重、死亡率更高，且患有基础疾病也能加重病情、提高死亡率。
    AIM: To evaluate the correlation between COVID-19 and heart injury through meta analysis, and to provide evidence-based basis for clinical practice. Methods: Wanfang, CNKI, Chinese biomedical literature database, PubMed, Embase, Cochrane Library, Medline database were searched by computer to retrieve studies related to COVID-19 infection and heart injury. The search time ranges from January 1, 2020 to April 20, 2020. Rev Man5.3 and STATA software were used to analyze the included studies. Results: A total of 29 studies were included, totaling 4466 patients. The results of the meta analysis showed that the critically ill patients had higher troponin than the non-critical patients (p = 0.03); the patients with myocardial injury were more serious and had higher mortality (p = 0.002; p = 0.0001); furthermore, patients with coronary heart disease, diabetes, or high blood pressure have more severe and higher mortality rates after infection with COVID-19 (p &lt; 0.01); CK-MB, AST, MYO, NT-proBNP also had some value in judging the severity of the disease. Conclusion: The COVID-19 patients with heart injury are more serious, and have a higher mortality rate, and having basic diseases can also aggravate the condition and increase the mortality rate. 
  
 
</p></abstract><kwd-group><kwd>新型冠状病毒肺炎，心脏损伤，合并症，Meta分析, COVID-19</kwd><kwd> Heart Injury</kwd><kwd> Complications</kwd><kwd> Meta Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>新型冠状病毒肺炎与心脏损伤相关性的 Meta分析<sup> </sup></title><p>潘小玉<sup>1,2*</sup>，张再伟<sup>2,3#</sup>，李 虎<sup>2</sup>，周中兴<sup>2</sup>，崔志远<sup>2</sup>，陈莎莎<sup>2</sup>，马 杰<sup>2</sup>，侯丽娟<sup>2</sup>，李 颖<sup>2</sup></p><p><sup>1</sup>济宁医学院临床医学院，山东 济宁</p><p><sup>2</sup>济宁市第一人民医院心血管内科，山东 济宁</p><p><sup>3</sup>济宁市第一人民医院心血管病研究所，山东 济宁</p><disp-formula id="hanspub.36934-formula38"><graphic xlink:href="//html.hanspub.org/file/4-1571476x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年7月18日；录用日期：2020年8月3日；发布日期：2020年8月10日</p><disp-formula id="hanspub.36934-formula39"><graphic xlink:href="//html.hanspub.org/file/4-1571476x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：通过meta分析评价新型冠状病毒肺炎与心脏损伤的相关性，为临床提供循证依据。方法：计算机检索万方、知网、中国生物医学文献数据库、PubMed、Embase、Cochrane Library、Medline数据库，检索感染新型冠状病毒肺炎与心脏损伤的相关研究，检索时间区间均从2020年1月1日至2020年4月20日。对于纳入的研究，应用Rev Man5.3及STATA软件进行分析。结果：总共纳入29项研究，合计4466名患者。Meta分析结果示：危重型患者比非危重型患者有更高的肌钙蛋白(p = 0.03)；合并心肌损伤的患者病情更重、死亡率更高(p = 0.002; p &lt; 0.0001)；此外，患有冠心病、糖尿病或高血压的患者感染新型冠状病毒肺炎后比普通人群感染后病情更重，死亡率更高(p &lt; 0.01)；CK-MB、AST、肌红蛋白、NT-proBNP也对判断病情严重程度有一定价值。结论：合并心脏损伤的新冠肺炎患者病情更重、死亡率更高，且患有基础疾病也能加重病情、提高死亡率。</p><p>关键词 :新型冠状病毒肺炎，心脏损伤，合并症，Meta分析</p><disp-formula id="hanspub.36934-formula40"><graphic xlink:href="//html.hanspub.org/file/4-1571476x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1571476x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1571476x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>2019年12月底，在武汉爆发了一场急性呼吸系统疾病，现已正式命名为COVID-19 (coronavirus disease 2019)或冠状病毒疾病2019 [<xref ref-type="bibr" rid="hanspub.36934-ref1">1</xref>]。截至2020年4月22日，全世界报告的新冠状病毒(COVID-2019)感染病例共有2,567,556例(中国84,289例，境外2,483,267例)，造成177,737人死亡，至少三分之一的全球人口处于某种形式的封锁状态。世卫组织(WHO)于2020年1月30日宣布新的冠状病毒肺炎的爆发为国际关注的公共卫生紧急情况(PHEIC)，并于2020年3月11日宣布为全球大流行。</p><p>感染新冠肺炎的患者若出现休克、急性呼吸窘迫综合征(ARDS)、急性心脏损伤和急性肾损伤，则会导致更高的死亡率。目前已有病例报道表明合并心脏损伤的患者往往病情较重 [<xref ref-type="bibr" rid="hanspub.36934-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.36934-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.36934-ref4">4</xref>]。本文通过系统检索，分析了心脏损伤与新冠肺炎的相关性，为临床诊疗提供循征学证据。</p></sec><sec id="s4"><title>2. 对象和方法</title><sec id="s4_1"><title>2.1. 对象</title><p>计算机检索万方、知网、维普、中国生物医学文献数据库、PubMed、Embase、Cochrane Library、Medline等数据库，中文检索词包括：“新型冠状病毒肺炎”、“新冠肺炎”、“新型冠状病毒”、“COVID-19”、“心脏”、“心肌”、“心肌炎”、“心血管”等；英文检索词包括：“novel coronavirus pneumonia”、“pneumonia”、“COVID-19”、“HCoV”、“SARS-CoV-2”、“COVID*”、“NCP*”、“cardiac”、“heart”、“myocardium”、“cardiovascular”、“myocarditis”，并手工纳入参考文献有关的研究。</p></sec><sec id="s4_2"><title>2.2. 纳入及排除标准</title><sec id="s4_2_1"><title>2.2.1. 纳入标准</title><p>① 研究类型：队列研究、横断面研究及病例对照研究。② 研究对象：新型冠状病毒肺炎感染者，其年龄、其他合并症不限。③ 结局指标：检测心脏损伤的相关指标，或报道合并进行心脏损伤。</p></sec><sec id="s4_2_2"><title>2.2.2. 排除标准</title><p>① 非本次新型冠状病毒感染的肺炎。② 重复文献。③ 未获得全文、综述、无主要结局指标的文献。</p></sec><sec id="s4_2_3"><title>2.2.3. 资料提取和质量评价</title><p>对按检索策略检索到的中英文文献由两名研究者独立筛选文献。筛选过程主要包括：首先排除重复检索的文献；其次阅读标题和摘要剔除不相关的研究；然后阅读全文确定满足标注的文献并进行数据提取；最后研究者之间进行交叉核对，若出现分歧与第三名研究者进行讨论。</p><p>本研究用美国卫生保健质量和研究机构(Agency for Healthcare Research and Quality, AHQR)工具进行质量评价。NOS评分量表适用于横断面研究，总共包括11个条目，每个条目回答“是”为1分，“否”为0分。低质量：0~3分；中等质量：4~7分；高质量：8~11分。同样由两名研究者独立评价，最后整合，若分歧较大，则由第三名研究者再次评价。</p></sec></sec><sec id="s4_3"><title>2.3. 统计学分析</title><p>使用Excel对数据进行初步整理，各数据(除年龄外)均使用x &#177; S表示，如果研究数据使用中位数和四分位数范围(Q25, Q75)表示，则假定中值等于平均值，标准差(SD)为(Q75-Q25)/2。后使用STATA和Review Manager 5.3软件进行分析。二分类变量用OR值表示，连续性变量用MD表示，区间估计均采用95%CI。研究间的异质性用I<sup>2</sup>值表示，0 ≤ I<sup>2</sup> &lt; 25%提示无异质性；25% ≤ I<sup>2</sup> ≤ 50%提示各研究间异质性较低；50% &lt; I<sup>2</sup> ≤ 75%提示中等异质性；I<sup>2</sup> &gt; 75%提示研究间异质性较大。当I<sup>2</sup> &gt; 50%首先进行异质性分析，若无明显临床异质性则采用随机效应模型，并使用STATA软件进行敏感性分析。当I<sup>2</sup> ≤ 50%时则采用固定效应模型。</p><p>为评估纳入文献是否存在发表偏倚，我们使用STATA软件对纳入文献绘制漏斗图进行定性分析，然后使用Egger’s检验进行定量分析，若p &lt; 0.05提示存在发表偏倚。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 文献检索结果</title><p>根据检索策略初步检索文献为2719篇，在去除重复文献、初步筛选及阅读全文筛选排除不符合纳入标准的文献后，最终纳入文献29篇(图1)。总共4466名患者，包括危重型、非危重型、生存患者和死亡患者。纳入研究的基本特征见表1、表2。</p></sec><sec id="s5_2"><title>3.2. 研究质量评估结果</title><p>本研究采用AHRQ评分系统，对纳入文献进行质量评价。结果显示评分最低为6分，最高为10分，平均(8.62 &#177; 3.52)分，处于中等偏上水平(评分见表1、表2)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of the studies included in the meta-analysis(less severe/more severe</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >作者</th><th align="center" valign="middle"  rowspan="2"  >地区</th><th align="center" valign="middle"  rowspan="2"  >质量 评分</th><th align="center" valign="middle"  rowspan="2"  >样本量</th><th align="center" valign="middle"  colspan="2"  >年龄</th><th align="center" valign="middle"  colspan="2"  >性别(男/总)</th><th align="center" valign="middle"  colspan="3"  >合并症(非危重组/危重组)</th><th align="center" valign="middle"  rowspan="2"  >诊疗标准</th></tr></thead><tr><td align="center" valign="middle" >非危重组</td><td align="center" valign="middle" >危重组</td><td align="center" valign="middle" >非危重组</td><td align="center" valign="middle" >危重组</td><td align="center" valign="middle" >冠心病</td><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >高血压</td></tr><tr><td align="center" valign="middle" >彭昱东 [<xref ref-type="bibr" rid="hanspub.36934-ref5">5</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >62.0 (55.0, 67.5)</td><td align="center" valign="middle" >57.5 (54.0, 63.0)</td><td align="center" valign="middle" >44/96</td><td align="center" valign="middle" >9/16</td><td align="center" valign="middle" >52/10</td><td align="center" valign="middle" >19/4</td><td align="center" valign="middle" >82/10</td><td align="center" valign="middle" >《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》</td></tr><tr><td align="center" valign="middle" >刘欢 [<xref ref-type="bibr" rid="hanspub.36934-ref6">6</xref>]</td><td align="center" valign="middle" >湖南</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >41.22 &#177; 16.62</td><td align="center" valign="middle" >63.75 &#177; 9.53</td><td align="center" valign="middle" >14/32</td><td align="center" valign="middle" >2/4</td><td align="center" valign="middle" >4/1</td><td align="center" valign="middle" >2/3</td><td align="center" valign="middle" >5/1</td><td align="center" valign="middle" >《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》</td></tr><tr><td align="center" valign="middle" >李美瑜 [<xref ref-type="bibr" rid="hanspub.36934-ref7">7</xref>]</td><td align="center" valign="middle" >广州</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >54 (33, 62)</td><td align="center" valign="middle" >58 (56, 76.5)</td><td align="center" valign="middle" >21/53</td><td align="center" valign="middle" >8/13</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >3/9</td><td align="center" valign="middle" >2/1</td><td align="center" valign="middle" >《新型冠状病毒感染的肺炎诊疗方案(试行第七版)》</td></tr><tr><td align="center" valign="middle" >李翠芝 [<xref ref-type="bibr" rid="hanspub.36934-ref8">8</xref>]</td><td align="center" valign="middle" >广州</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >82</td><td align="center" valign="middle" >35.2 &#177; 13.8</td><td align="center" valign="middle" >57.8 &#177; 12.2</td><td align="center" valign="middle" >31/58</td><td align="center" valign="middle" >17/24</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >5/13</td><td align="center" valign="middle" >7/15</td><td align="center" valign="middle" >《新型冠状病毒感染的肺炎诊疗方案(试行第七版)》</td></tr><tr><td align="center" valign="middle" >陈晨 [<xref ref-type="bibr" rid="hanspub.36934-ref9">9</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >150</td><td align="center" valign="middle" >57.1 &#177; 15.6</td><td align="center" valign="middle" >68.5 &#177; 13.6</td><td align="center" valign="middle" >66/126</td><td align="center" valign="middle" >18/24</td><td align="center" valign="middle" >3/6</td><td align="center" valign="middle" >15/5</td><td align="center" valign="middle" >35/14</td><td align="center" valign="middle" >《新型冠状病毒感染的肺炎诊疗方案(试行第六版)》</td></tr><tr><td align="center" valign="middle" >程克斌 [<xref ref-type="bibr" rid="hanspub.36934-ref10">10</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >463</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >145/282</td><td align="center" valign="middle" >99/181</td><td align="center" valign="middle" >12/16</td><td align="center" valign="middle" >20/20</td><td align="center" valign="middle" >54/53</td><td align="center" valign="middle" >自定义</td></tr><tr><td align="center" valign="middle" >张权宇 [<xref ref-type="bibr" rid="hanspub.36934-ref11">11</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >52 &#177; 12</td><td align="center" valign="middle" >56 &#177; 12</td><td align="center" valign="middle" >15/34</td><td align="center" valign="middle" >24/31</td><td align="center" valign="middle" >2/5</td><td align="center" valign="middle" >3/4</td><td align="center" valign="middle" >7/11</td><td align="center" valign="middle" >《新型冠状病毒感染的肺炎诊疗方案(试行第五版)》</td></tr><tr><td align="center" valign="middle" >Huang Chaolin [<xref ref-type="bibr" rid="hanspub.36934-ref12">12</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >49.0 (41.0~57.5)</td><td align="center" valign="middle" >49.0 (41.0~61.0)</td><td align="center" valign="middle" >19 /28</td><td align="center" valign="middle" >11 /13</td><td align="center" valign="middle" >3/3</td><td align="center" valign="middle" >7/1</td><td align="center" valign="middle" >4/2</td><td align="center" valign="middle" >是否入住ICU</td></tr><tr><td align="center" valign="middle" >Cai Qingxian [<xref ref-type="bibr" rid="hanspub.36934-ref13">13</xref>]</td><td align="center" valign="middle" >深圳</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >298</td><td align="center" valign="middle" >40.0 (31.0~56.0)</td><td align="center" valign="middle" >64.0 (56.0~66.0)</td><td align="center" valign="middle" >111/240</td><td align="center" valign="middle" >33/58</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >国际社区获得性肺炎指南</td></tr><tr><td align="center" valign="middle" >JiDong [<xref ref-type="bibr" rid="hanspub.36934-ref14">14</xref>]</td><td align="center" valign="middle" >北京</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >37.9 (14.2)</td><td align="center" valign="middle" >56.5 (16.5)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >自定义</td></tr><tr><td align="center" valign="middle" >Lu Hongzhou [<xref ref-type="bibr" rid="hanspub.36934-ref15">15</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >263</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >10/4</td><td align="center" valign="middle" >15/6</td><td align="center" valign="middle" >42/10</td><td align="center" valign="middle" >《新型冠状病毒感染的肺炎诊疗方案(试行第五版)》</td></tr><tr><td align="center" valign="middle" >Wang Dawei [<xref ref-type="bibr" rid="hanspub.36934-ref16">16</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >138</td><td align="center" valign="middle" >51 (37~62)</td><td align="center" valign="middle" >66 (57~78)</td><td align="center" valign="middle" >53 /102</td><td align="center" valign="middle" >22 /36</td><td align="center" valign="middle" >11/9</td><td align="center" valign="middle" >6/8</td><td align="center" valign="middle" >22/21</td><td align="center" valign="middle" >是否入住ICU</td></tr><tr><td align="center" valign="middle" >Zhou Bo [<xref ref-type="bibr" rid="hanspub.36934-ref17">17</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >63 (58~69)</td><td align="center" valign="middle" >67 (66~75)</td><td align="center" valign="middle" >12/26</td><td align="center" valign="middle" >5/8</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >《新型冠状病毒感染的肺炎诊疗方案(试行第四版)》</td></tr><tr><td align="center" valign="middle" >Wang Guyi [<xref ref-type="bibr" rid="hanspub.36934-ref18">18</xref>]</td><td align="center" valign="middle" >长沙</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >242</td><td align="center" valign="middle" >41 (1~84)</td><td align="center" valign="middle" >57 (25~75)</td><td align="center" valign="middle" >99/205</td><td align="center" valign="middle" >20/37</td><td align="center" valign="middle" >4/5</td><td align="center" valign="middle" >11/4</td><td align="center" valign="middle" >22/14</td><td align="center" valign="middle" >自定义</td></tr><tr><td align="center" valign="middle" >Wan Suxin [<xref ref-type="bibr" rid="hanspub.36934-ref19">19</xref>]</td><td align="center" valign="middle" >重庆</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >135</td><td align="center" valign="middle" >44 (33~49)</td><td align="center" valign="middle" >56 (52~73)</td><td align="center" valign="middle" >52/95</td><td align="center" valign="middle" >21/40</td><td align="center" valign="middle" >1/6</td><td align="center" valign="middle" >3/9</td><td align="center" valign="middle" >9/4</td><td align="center" valign="middle" >自定义</td></tr><tr><td align="center" valign="middle" >Y.H. [<xref ref-type="bibr" rid="hanspub.36934-ref20">20</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >64.74 (41~81)</td><td align="center" valign="middle" >65.08 (31~87)</td><td align="center" valign="middle" >9 /23</td><td align="center" valign="middle" >17/24</td><td align="center" valign="middle" >1/4</td><td align="center" valign="middle" >3/4</td><td align="center" valign="middle" >8/10</td><td align="center" valign="middle" >自定义</td></tr><tr><td align="center" valign="middle" >Ma Kun-Long [<xref ref-type="bibr" rid="hanspub.36934-ref21">21</xref>]</td><td align="center" valign="middle" >重庆</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >46.5 (39.2~54.8)</td><td align="center" valign="middle" >58.0 (48.5~74.5)</td><td align="center" valign="middle" >36/64</td><td align="center" valign="middle" >12/20</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >3/7</td><td align="center" valign="middle" >8/4</td><td align="center" valign="middle" >《新型冠状病毒感染的肺炎诊疗方案(试行第五版)》</td></tr></tbody></table></table-wrap><p>表1. 纳入研究基本特征(非危重组/危重组)</p><p>图1. 文献筛选流程图</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Characteristics of the studies included in the meta-analysis (survival/death</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >作者</th><th align="center" valign="middle"  rowspan="2"  >地区</th><th align="center" valign="middle"  rowspan="2"  >质量评分</th><th align="center" valign="middle"  rowspan="2"  >样本量</th><th align="center" valign="middle"  colspan="2"  >年龄</th><th align="center" valign="middle"  colspan="2"  >性别(男/总)</th><th align="center" valign="middle"  colspan="3"  >合并症(生存/死亡)</th></tr></thead><tr><td align="center" valign="middle" >生存</td><td align="center" valign="middle" >死亡</td><td align="center" valign="middle" >生存</td><td align="center" valign="middle" >死亡</td><td align="center" valign="middle" >冠心病</td><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >高血压</td></tr><tr><td align="center" valign="middle" >王朗 [<xref ref-type="bibr" rid="hanspub.36934-ref22">22</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >202</td><td align="center" valign="middle" >61 (49, 67)</td><td align="center" valign="middle" >74 (65, 84)</td><td align="center" valign="middle" >65/169</td><td align="center" valign="middle" >23/33</td><td align="center" valign="middle" >11/5</td><td align="center" valign="middle" >18/4</td><td align="center" valign="middle" >44/16</td></tr><tr><td align="center" valign="middle" >彭昱东 [<xref ref-type="bibr" rid="hanspub.36934-ref23">23</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >62.0 (55.0, 67.5)</td><td align="center" valign="middle" >57.5 (54.0, 63.0)</td><td align="center" valign="middle" >-/95</td><td align="center" valign="middle" >-/17</td><td align="center" valign="middle" >47/15</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >77/15</td></tr><tr><td align="center" valign="middle" >贺行巍 [<xref ref-type="bibr" rid="hanspub.36934-ref24">24</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >66.5 (56.0, 71.8)</td><td align="center" valign="middle" >70.0 (62.5, 76.5)</td><td align="center" valign="middle" >18/28</td><td align="center" valign="middle" >16/26</td><td align="center" valign="middle" >3/5</td><td align="center" valign="middle" >5/8</td><td align="center" valign="middle" >12/12</td></tr><tr><td align="center" valign="middle" >Yang Xiaobo [<xref ref-type="bibr" rid="hanspub.36934-ref25">25</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >51.9 (12.9)</td><td align="center" valign="middle" >64.6 (11.2)</td><td align="center" valign="middle" >14/20</td><td align="center" valign="middle" >21/32</td><td align="center" valign="middle" >2/2</td><td align="center" valign="middle" >3/7</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Zhou Fei [<xref ref-type="bibr" rid="hanspub.36934-ref26">26</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >191</td><td align="center" valign="middle" >52.0 (45.0, 58.0)</td><td align="center" valign="middle" >69.0 (63.0, 76.0)</td><td align="center" valign="middle" >81/137</td><td align="center" valign="middle" >38/54</td><td align="center" valign="middle" >2/13</td><td align="center" valign="middle" >19/17</td><td align="center" valign="middle" >32/26</td></tr><tr><td align="center" valign="middle" >Fu Lin [<xref ref-type="bibr" rid="hanspub.36934-ref27">27</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >83/166</td><td align="center" valign="middle" >16/34</td><td align="center" valign="middle" >14/2</td><td align="center" valign="middle" >111/26</td><td align="center" valign="middle" >79/22</td></tr><tr><td align="center" valign="middle" >Ruan Qiurong [<xref ref-type="bibr" rid="hanspub.36934-ref28">28</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >150</td><td align="center" valign="middle" >50 (44, 81)</td><td align="center" valign="middle" >67 (15, 81)</td><td align="center" valign="middle" >53/82</td><td align="center" valign="middle" >49/68</td><td align="center" valign="middle" >5/7</td><td align="center" valign="middle" >13/12</td><td align="center" valign="middle" >23/29</td></tr><tr><td align="center" valign="middle" >Chen Tao [<xref ref-type="bibr" rid="hanspub.36934-ref29">29</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >274</td><td align="center" valign="middle" >51.0 (37.0, 66.0)</td><td align="center" valign="middle" >68.0 (62.0, 77.0)</td><td align="center" valign="middle" >88/161</td><td align="center" valign="middle" >83/113</td><td align="center" valign="middle" >7/16</td><td align="center" valign="middle" >23/24</td><td align="center" valign="middle" >39/54</td></tr><tr><td align="center" valign="middle" >Zhang Fan [<xref ref-type="bibr" rid="hanspub.36934-ref30">30</xref>]</td><td align="center" valign="middle" >武汉</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >66.16 &#177; 13.66</td><td align="center" valign="middle" >78.65 &#177; 8.31</td><td align="center" valign="middle" >21/31</td><td align="center" valign="middle" >12/17</td><td align="center" valign="middle" >9/5</td><td align="center" valign="middle" >4/5</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>表2. 纳入研究基本特征(生存/死亡)</p></sec><sec id="s5_3"><title>3.3. Meta分析结果</title><sec id="s5_3_1"><title>3.3.1. 肌钙蛋白与新冠肺炎严重程度的相关性</title><p>11项研究按照新冠肺炎诊断标准，将患者分为危重型和非危重型，并检测血浆肌钙蛋白的水平。Meta分析结果示：危重组(危重型)相比于非危重组(非危重型)肌钙蛋白升高[MD = 0.02, 95% CI (0.00, 0.03), p = 0.03]，差异有明显的统计学意义。森林图见图2。</p><p>图2. 危重型与非危重型肌钙蛋白水平森林图</p></sec><sec id="s5_3_2"><title>3.3.2. 心脏损伤与新冠肺炎相关性分析</title><p>8项研究 [<xref ref-type="bibr" rid="hanspub.36934-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.36934-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.36934-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.36934-ref33">33</xref>] 分析了生存组与死亡组发生心脏损伤的比例，从而验证是否心脏损伤与更高的死亡率有关。结果表明死亡组心脏损伤的发生率明显高于生存组[OR = 12.9, 95% CI (4.03, 41.39), p &lt; 0.0001]，差异有明显的统计学意义。有5项研究比较了危重组与非危重组心脏损伤的发生率，结果表明发生心脏损伤的患者往往病情更重[OR = 6.35, 95% CI (1.95, 20.71), p = 0.002]。森林图见图3、图4。</p><p>图3. 危重型与非危重型心脏损伤发生率森林图</p><p>图4. 生存者与死亡者心脏损伤发生率森林图</p></sec><sec id="s5_3_3"><title>3.3.3. 基础疾病与新冠肺炎相关性分析</title><p>17项研究将患者分为危重症组与非危重症组，然后从基础疾病的角度分析基础疾病与新冠肺炎严重程度的相关性。结果表明：合并冠心病、糖尿病或高血压的患者比无基础疾病的患者病情更严重(p均 &lt; 0.001)。9项研究通过对生存患者及死亡患者基础疾病的对比，发现合并冠心病、糖尿病或高血压的患者死亡率明显增高(p = 0.002; p = 0.0002; p &lt; 0.00001)。其中合并高血压的患者死亡率最高。森林图见图5、图6。</p><p>图5. 危重型与非危重型合并症发生率森林图</p></sec><sec id="s5_3_4"><title>3.3.4. 与新冠肺炎相关的其他心脏指标</title><p>4项研究报道了肌红蛋白的水平，结果提示在危重型患者中肌红蛋白比非危重型患者有升高趋势，但无统计学意义(p = 0.07)；8项研究报道了AST水平、9项研究检测了CK-MB的水平，结果表明：危重组患者AST或CK-MB比非危重组明显升高(p = 0.0003, p = 0.0002)；此外NT-proBNP作为评价心功能的指标，3项研究对其进行报道，表明NT-proBNP也可作为新冠肺炎患者病情严重程度的指标(p &lt; 0.0001)。森林图见图7、图8。</p></sec></sec><sec id="s5_4"><title>3.4. 敏感性分析</title><p>由于各研究质量及样本量差异的存在，导致各研究间异质性较大，为验证数据的可靠性，我们进行了敏感性分析。以危重组与非危重组之间肌钙蛋白的差异为例进行敏感性分析，结果表明，去除各项研究后合并效应值均在0.37~0.69之间波动，提示meta分析结果较为可靠(图9)。</p><p>图6. 生存者与死亡者合并症发生率森林</p><p>图7. 危重型与非危重型CK-MB水平森林图</p></sec><sec id="s5_5"><title>3.5. 发表偏倚结果</title><p>首先使用漏斗图对纳入文献进行发表偏倚定性分析(以危重组与非危重组之间肌钙蛋白的差异为例)，显示分布稍不对称，为进一步验证，我们使用Egger’s检验，结果表明：p = 0.477 (&gt;0.05)无发表偏倚(见图10)。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>本研究通过比较危重型患者于非危重型患者、生存者与死亡者的心脏损伤指标，发现合并心脏损伤或心脏标志物较高的患者病情较重，且死亡率较高。为了解基础疾病与新冠肺炎的相关性，本研究通过亚组分析比较了合并冠心病、糖尿病、高血压与普通患者的临床特征，结果表明，合并冠心病、糖尿病或高血压的患者危重型较多，预后较差，其中合并高血压的患者死亡率更高。大多数研究合并结果异质性低，meta分析结果较为可靠。对于异质性较高的，本研究进行敏感性分析，均未发现明显异质性存在，同时对此类研究采用随机效应模型分析。</p><p>图8. 危重型与非危重型其他心脏指标水平森林图</p><p>图9. 敏感性分析结果(危重型与非危重型肌钙蛋白水平)</p><p>图10. 发表偏倚漏斗图及Egger’s检验图</p><p>虽然COVID-19引起的心肌损伤的确切病理生理机制尚不完全清楚，在COVID-19患者中细胞因子风暴，可能导致冠状动脉血流减少、冠脉斑块破裂、微血栓形成，这可能导致心肌损伤 [<xref ref-type="bibr" rid="hanspub.36934-ref32">32</xref>]。此外病毒可通过ACE2入侵细胞，而ACE大量表达于心脏的血管内皮细胞中，因此存在COVID-19介导内皮细胞损伤的可能 [<xref ref-type="bibr" rid="hanspub.36934-ref34">34</xref>]。而且炎症风暴也可导致血管内皮细胞的损伤。还有研究表明，患者在感染冠状病毒的同时 [<xref ref-type="bibr" rid="hanspub.36934-ref35">35</xref>]，心血管疾病及相关疾病的发病率明显增高，可能与免疫系统的紊乱和全身炎症反应有关。COVID-19首先攻击肺脏，重症患者可导致肺通气和肺换气障碍，从而形成低氧血症。持续低氧会引起酸中毒、细胞内钙超载，引起心肌细胞的损伤。有研究提示合并基础疾病的患者(冠心病、糖尿病和高血压)感染冠状病毒后往往病情较重，预后较差 [<xref ref-type="bibr" rid="hanspub.36934-ref36">36</xref>]。</p><p>基于之前的临床研究及本研究结果，我们建议在新冠肺炎患者住院期间需要进行心脏损伤生物标志物的动态监测，尤其是合并基础疾病的患者，从而尽早识别是否合并心脏损伤，对于改善患者预后具有较高的价值。</p><p>局限性包括：① 大多数研究样本量较少，而且多为观察性或回顾性研究，必然存在多种偏倚；② 由于每个研究所处地区不同，各项指标的检测存在一定差异，而且大多数均报道了中位数和百分位，为进行系统分析，本研究进行了数据转化；③ 各地医疗水平不可避免的存在差异，这对患者的病情分类及治疗效果产生一定程度的影响。</p></sec><sec id="s7"><title>5. 结论</title><p>综上所述，合并心脏损伤的新冠肺炎患者病情更重、死亡率更高，心脏标志物可及早发现此类患者。此外患者合并冠心病、糖尿病或高血压也能显著影响其预后。但由于本研究受到研究质量等的限制，只能在现有的证据上，对新冠肺炎患者的综合管理提出参考意见，为改善患者预后，战胜疫情助力。</p></sec><sec id="s8"><title>文章引用</title><p>潘小玉,张再伟,李 虎,周中兴,崔志远,陈莎莎,马 杰,侯丽娟,李 颖. 新型冠状病毒肺炎与心脏损伤相关性的Meta分析Meta Analysis of the Correlation between COVID-19 and Heart Injury[J]. 临床医学进展, 2020, 10(08): 1554-1565. https://doi.org/10.12677/ACM.2020.108233</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36934-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, G., Hu, C., Luo, L., et al. (2020) Clinical Features and Short-Term Outcomes of 221 Patients with COVID-19 in Wuhan, China. Journal of Clinical Virology, 127, Article ID: 104364. &lt;br&gt;https://doi.org/10.1016/j.jcv.2020.104364</mixed-citation></ref><ref id="hanspub.36934-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Metzler, B., Siostrzonek, P., Binder, R.K., et al. (2020) Decline of Acute Coronary Syndrome Admissions in Austria since the Outbreak of COVID-19: The Pandemic Response Causes Cardiac Collateral Damage. European Heart Journal, 41, 1852-1853. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehaa314</mixed-citation></ref><ref id="hanspub.36934-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kochi, A.N., Tagliari, A.P., Forleo, G.B., et al. (2020) Cardiac and Arrhythmic Complications in Patients with COVID-19. Journal of Cardiovascular Electrophysiology, 31, 1003-1008. &lt;br&gt;https://doi.org/10.1111/jce.14479</mixed-citation></ref><ref id="hanspub.36934-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Han, Y.L. (2020) Initial COVID-19 Affecting Cardiac Patients in China. European Heart Journal, 41, 1719.</mixed-citation></ref><ref id="hanspub.36934-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">彭昱东, 孟凯, 官红权, 等. 心血管病患者感染新型冠状病毒肺炎112例临床特点及转归[J/OL]. 中华心血管病杂志, 2020, 48: E004. http://rs.yiigle.com/yufabiao/1183314.htm, 2020-03-02.</mixed-citation></ref><ref id="hanspub.36934-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">刘欢, 马小峰, 谭剑凯, 黄柯, 周琴怡, 姜志胜. COVID-19重型患者心肌损伤及心脏功能变化的初步观察[J]. 中国动脉硬化杂志, 2020, 28(4): 285-289.</mixed-citation></ref><ref id="hanspub.36934-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李美瑜, 吕明芳, 李翠芝, 童裕维, 李景隆, 雷春亮. 不同临床分型新型冠状病毒肺炎患者的心脏表现特征[J]. 广东医学, 2020, 41(8): 1-4.</mixed-citation></ref><ref id="hanspub.36934-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">李翠芝, 李美瑜, 甘露, 张影, 雷春亮. 新型冠状病毒肺炎患者合并心脏和肝脏损害的临床分析[J]. 广东医学, 2020, 41(9): 1-4.</mixed-citation></ref><ref id="hanspub.36934-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">陈晨, 陈琛, 严江涛, 等. 新型冠状病毒肺炎危重症患者心肌损伤及患有心血管基础疾病的情况分析[J/OL]. 中华心血管病杂志, 2020, 48. http://rs.yiigle.com/yufabiao/1183794.htm, 2020-03-06.</mixed-citation></ref><ref id="hanspub.36934-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">程克斌, 魏明, 沈虹, 吴超民, 陈德昌, 熊维宁, 周新, 张定宇, 郑军华. 普通型和重型新型冠状病毒肺炎康复患者463例临床特征分析[J/OL]. 上海医学, 2020: 1-15.  
http://kns.cnki.net/kcms/detail/31.1366.r.20200312.1254.004.html, 2020-04-22.</mixed-citation></ref><ref id="hanspub.36934-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">张权宇, 杨哲然, 李毅, 彭程飞, 于浩, 唐裕福, 滕玥, 史亮, 马壮, 韩雅玲. 新冠肺炎临床轻症患者冠心病及其危险因素临床特征总结[J/OL]. 心脏杂志, 2020, 32(2): 1-6.  
http://kns.cnki.net/kcms/detail/61.1268.r.20200407.0858.001.html, 2020-04-22.</mixed-citation></ref><ref id="hanspub.36934-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Huang, C., Wang, Y., Li, X., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet (London, England), 395, 497-506. &lt;br&gt;https://doi.org/10.1016/S0140-6736(20)30183-5</mixed-citation></ref><ref id="hanspub.36934-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Cai, Q., Huang, D., Ou, P., et al. (2020) 2019-nCoV Pneumonia in a Normal Work Infectious Diseases Hospital Besides Hubei Province, China. &lt;br&gt;https://ssrn.com/abstract=3542163  
&lt;br&gt;https://doi.org/10.2139/ssrn.3542163</mixed-citation></ref><ref id="hanspub.36934-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ji, D., Zhang, D., Chen, Z., et al. (2020) Clinical Characteristics Predicting Progression of COVID-19.  
&lt;br&gt;https://ssrn.com/abstract=3539674  
&lt;br&gt;https://doi.org/10.2139/ssrn.3539674</mixed-citation></ref><ref id="hanspub.36934-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lu, H., Ai, J., Shen, Y., et al. (2020) A Descriptive Study of the Impact of Diseases Control and Prevention on the Epidemics Dynamics and Clinical Features of SARS-CoV-2 Outbreak in Shanghai, Lessons Learned for Metropolis Epidemics Prevention. &lt;br&gt;https://doi.org/10.1101/2020.02.19.20025031</mixed-citation></ref><ref id="hanspub.36934-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wang, D., Hu, B., Hu, C., et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. &lt;br&gt;https://doi.org/10.1001/jama.2020.1585</mixed-citation></ref><ref id="hanspub.36934-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, B., She, J., Wang, Y., et al. (2020) The Clinical Characteristics of Myocardial Injury in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease. Journal of Infection, 81, 147-178. &lt;br&gt;https://ssrn.com/abstract=3539668  
&lt;br&gt;https://doi.org/10.2139/ssrn.3539668</mixed-citation></ref><ref id="hanspub.36934-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wang, G., Wu, C., Zhang, Q., et al. (2020) Epidemiological and Clinical Features of Corona Virus Disease 2019 (COVID-19) in Changsha, China. &lt;br&gt;https://ssrn.com/abstract=3548770  
&lt;br&gt;https://doi.org/10.2139/ssrn.3548770</mixed-citation></ref><ref id="hanspub.36934-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Wan, S., Xiang, Y., Fang, W., et al. (2020) Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. Journal of Medical Virology, 92, 797-806. &lt;br&gt;https://doi.org/10.1002/jmv.25783</mixed-citation></ref><ref id="hanspub.36934-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Han, Y., Zhang, H., Mu, S., et al. (2020) Lactate Dehydrogenase, a Risk Factor of Severe COVID-19 Patients.  
&lt;br&gt;https://doi.org/10.1101/2020.03.24.20040162</mixed-citation></ref><ref id="hanspub.36934-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ma, K., Liu, Z., Cao, C., et al. (2020) COVID-19 Myocarditis and Severity Factors: An Adult Cohort Study.  
&lt;br&gt;https://doi.org/10.1101/2020.03.19.20034124</mixed-citation></ref><ref id="hanspub.36934-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">王朗, 何文博, 余小梅, 等. 心肌损伤对新型冠状病毒肺炎患者临床预后的影响[J/OL]. 中华心血管病杂志, 2020, 48. http://rs.yiigle.com/yufabiao/1188751.htm, 2020-04-14.</mixed-citation></ref><ref id="hanspub.36934-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">贺行巍, 赖金胜, 程佳, 等. 重型/危重型新型冠状病毒肺炎患者合并心肌损伤对预后的影响[J/OL]. 中华心血管病杂志, 2020, 48. http://rs.yiigle.com/yufabiao/1184840.htm, 2020-03-15.</mixed-citation></ref><ref id="hanspub.36934-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yang, X., Yu, Y., Xu, J., et al. (2020) Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. The Lancet Respiratory Medicine, 8, 475-481. &lt;br&gt;https://doi.org/10.1016/S2213-2600(20)30079-5</mixed-citation></ref><ref id="hanspub.36934-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, F., Yu, T., Du, R., et al. (2020) Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. The Lancet (London, England), 395, 1054-1062.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(20)30566-3</mixed-citation></ref><ref id="hanspub.36934-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Fu, L., Fei, J., Xiang, H., et al. (2020) Influence Factors of Death Risk among COVID-19 Patients in Wuhan, China: A Hospital-Based Case-Cohort Study. &lt;br&gt;https://doi.org/10.21203/rs.3.rs-26775/v1</mixed-citation></ref><ref id="hanspub.36934-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ruan, Q., Yang, K., Wang, W., et al. (2020) Correction to: Clinical Predictors of Mortality Due to COVID-19 Based on an Analysis of Data of 150 Patients from Wuhan, China. Intensive Care Medicine.  
&lt;br&gt;https://doi.org/10.1007/s00134-020-06028-z</mixed-citation></ref><ref id="hanspub.36934-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Chen, T., Wu, D., Chen, H., et al. (2020) Clinical Characteristics of 113 Deceased Patients with Coronavirus Disease 2019: Retrospective Study. BMJ (Clinical Research ed.), 368, m1091. &lt;br&gt;https://doi.org/10.1136/bmj.m1091</mixed-citation></ref><ref id="hanspub.36934-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, F., Yang, D., Li, J., et al. (2020) Myocardial Injury Is Associated with In-Hospital Mortality of Confirmed or Suspected COVID-19 in Wuhan, China: A Single Center Retrospective Cohort Study.  
&lt;br&gt;https://doi.org/10.1101/2020.03.21.20040121</mixed-citation></ref><ref id="hanspub.36934-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Li, J., Liu, D., et al. (2020) Clinical Features and Outcomes of 2019 Novel Coronavirus-Infected Patients with Cardiac Injury. &lt;br&gt;https://doi.org/10.1101/2020.03.11.20030957</mixed-citation></ref><ref id="hanspub.36934-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Shi, S., Qin, M., Shen, B., et al. (2020) Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. &lt;br&gt;https://doi.org/10.1001/jamacardio.2020.0950</mixed-citation></ref><ref id="hanspub.36934-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Guo, T., Fan, Y., Chen, M., et al. (2020) Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 5, 811-818. &lt;br&gt;https://doi.org/10.1001/jamacardio.2020.1017</mixed-citation></ref><ref id="hanspub.36934-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Chen, J., Fan, H., Zhang, L., et al. (2020) Retrospective Analysis of Clinical Features in 101 Death Cases with COVID-19. &lt;br&gt;https://doi.org/10.1101/2020.03.09.20033068</mixed-citation></ref><ref id="hanspub.36934-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Xu, X., Chen, P., Wang, J., et al. (2020) Evolution of the Novel Coronavirus from the Ongoing Wuhan Outbreak and Modeling of Its Spike Protein for Risk of Human Transmission. Science China Life Sciences, 63, 457-460.  
&lt;br&gt;https://doi.org/10.1007/s11427-020-1637-5</mixed-citation></ref><ref id="hanspub.36934-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Chen, N., Zhou, M., Dong, X., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet, 395, 507-513.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(20)30211-7</mixed-citation></ref><ref id="hanspub.36934-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Hui, H., Yang, H., Wang, X., et al. (2020) Clinical and Radiographic Features of Cardiac Injury in Patients with 2019 Novel Coronavirus Pneumonia. &lt;br&gt;https://doi.org/10.1101/2020.02.24.20027052</mixed-citation></ref></ref-list></back></article>